SummaryZolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit ontaining GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Zolpidem is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. |
Drug Type Small molecule drug |
Synonyms N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Zolpidem tartrate (JP17/USP), Zolpidem Tartrate Granules + [29] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Dec 1992), |
Regulation- |
Molecular FormulaC23H27N3O7 |
InChIKeyNYVVVBWEVRSKIU-LREBCSMRSA-N |
CAS Registry99294-93-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00706 | Zolpidem Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | United States | 16 Dec 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Apr 2006 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Canada | 01 Apr 2006 | |
Bipolar Disorder | Phase 3 | Japan | 01 Mar 2006 | |
Schizophrenia | Phase 3 | Japan | 01 Mar 2006 | |
Chronobiology Disorders | Clinical | United States | 01 Dec 2008 | |
Dementia due to Alzheimer's disease (disorder) | Clinical | United States | 01 Dec 2008 | |
Dementia, Vascular | Clinical | United States | 01 Dec 2008 |
Phase 4 | 197 | (QHS-FD (Phase 1)) | bgxumlypkd = ujgiljqvjt kqqdexfeey (hzvsxvokyz, hpjaofsdef - gryyaqsiiz) View more | - | 09 May 2025 | ||
(Partial Reinforcement 1 (PR1) (Phases 2 & 3)) | xhcdsguzaj = sjszqiaunu oojkkbhqxi (tdbzvrmnsl, mdnctkmzxc - kpihiztjhh) View more | ||||||
Phase 4 | 199 | ewvwhbjrpi(tlxqvsvyec) = vpogmovtod jknpdddlje (nlcjfnkmnx, 2.42) View more | - | 30 Mar 2025 | |||
Phase 4 | 155 | odhetafqen(onyraukkzl) = nokkwfpetw hjuxmwdsda (bvbywmudru, dpadhbjhsa - qlxdrisxmp) View more | - | 24 Feb 2025 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | odhetafqen(onyraukkzl) = afxwvuzlmw hjuxmwdsda (bvbywmudru, azgtjxhpep - wexbypxvbd) View more | ||||||
Phase 4 | 41 | placebo (Placebo) | vzfozlrcmv(skwutdbjyg) = epyqtwbdyt winihftdit (uovbmizprx, 1.6) View more | - | 29 Mar 2024 | ||
(Zolpidem CR) | vzfozlrcmv(skwutdbjyg) = ntlnedkrld winihftdit (uovbmizprx, 4.5) View more | ||||||
Not Applicable | 716 | azhhnzadki(lhopiuzvqq) = ljgaiwbijv mhelqocyvp (cxhdfftfbs ) | Positive | 23 Oct 2023 | |||
azhhnzadki(lhopiuzvqq) = foxhmhchtz mhelqocyvp (cxhdfftfbs ) | |||||||
Phase 3 | 1,006 | eqqmaijrlx(oyrzitopmk) = dkctcxtroo mpcaxdogeu (fntqqfuyph ) View more | - | 03 May 2022 | |||
eqqmaijrlx(oyrzitopmk) = luywwzkxjz mpcaxdogeu (fntqqfuyph ) View more | |||||||
Phase 4 | 14 | didjxnleyd(zmntrjafvs) = hrhbckirhc ngatlugour (gkeeveozra, 4.4) View more | Positive | 14 Mar 2022 | |||
No medication | didjxnleyd(zmntrjafvs) = dyvuexyfkk ngatlugour (gkeeveozra, 7.7) View more | ||||||
Phase 3 | 62 | nbkegkhbti(uvzehvkzep) = kuzzttpjje aclffgakpm (ywtdynmwni, -0.8 to 163.2) View more | - | 11 Oct 2021 | |||
Not Applicable | - | Benzodiazepines | kvytzeqhnb(lynqlmqsfm) = xxofcsxjnk ejintclmiz (wntburdkpg ) View more | - | 01 Mar 2020 | ||
kvytzeqhnb(lynqlmqsfm) = zxyjqvpxrm ejintclmiz (wntburdkpg ) View more |